文献
J-GLOBAL ID:201702276697500230
整理番号:17A0685240
EGFR変異陽性肺腺癌に対するアファチニブの安全性と有効性に及ぼす用量調節の影響 無作為化LUX-Lung 3および6試験の事後解析
Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials
著者 (21件):
YANG J. C.-H.
(National Taiwan Univ. Hospital, Taipei, TWN)
,
SEQUIST L. V.
(Harvard Medical School, Boston, USA)
,
ZHOU C.
(Tongji Univ., Shanghai, CHN)
,
SCHULER M.
(Univ. Duisburg-Essen, Essen, DEU)
,
GEATER S. L.
(Prince of Songkla Univ., Songkhla, THA)
,
MOK T.
(Chinese Univ. Hong Kong, HKG)
,
HU C.-P.
(Central South Univ., Changsha, CHN)
,
YAMAMOTO N.
(Wakayama Medical Univ., Wakayama, JPN)
,
FENG J.
(Jiangsu Province Cancer Hospital, Jiangsu, CHN)
,
O’BYRNE K.
(Queensland Univ. Technol., Brisbane, AUS)
,
LU S.
(Shanghai Jiao Tong Univ., Shanghai, CHN)
,
HIRSH V.
(McGill Univ., Montreal, CAN)
,
HUANG Y.
(Yunnan Tumor Hospital, Yunnan Province, CHN)
,
SEBASTIAN M.
(Johann Wolfgang Goethe Univ. Medical Center, Frankfurt am Main, DEU)
,
OKAMOTO I.
(Kyushu Univ., Fukuoka, JPN)
,
DICKGREBER N.
(Thoracic Oncology and Respiratory Care Medicine, Rheine, DEU)
,
SHAH R.
(Maidstone Hospital, Kent, GBR)
,
MAERTEN A.
(Boehringer Ingelheim GmbH, Co. KG, Ingelheim am Rhein, DEU)
,
MASSEY D.
(Boehringer Ingelheim Ltd UK, Bracknell, Berkshire, GBR)
,
WIND S.
(Boehringer Ingelheim Pharma GmbH, Co. KG, Biberach, DEU)
,
WU Y.-L.
(Guangdong Acad. of Medical Sci., Guangzhou, CHN)
資料名:
Annals of Oncology
(Annals of Oncology)
巻:
27
号:
11
ページ:
2103-2110
発行年:
2016年11月
JST資料番号:
W0107A
ISSN:
0923-7534
CODEN:
ANONE2
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
イギリス (GBR)
言語:
英語 (EN)